Decentralized and Digital Clinical Research in Pharmacology: Opportunities and Challenges

Rutuja F. Sontakke, Komal S. Hiray, Yuvraj S. Ahire, Gitanjali S. Deokar

MET Institute Of Pharmacy .BKC, Nashik

Corresponding author: *Rutuja F. Sontakke*
Email: rutujasontakke07@gmail.com
Doi: **10.5281/zenodo.17101793**
Received: 25 July 2025
Accepted: 05 August 2025

Abstract

Pharmacological trials are changing from traditional, site-centric methods to more adaptable, patient-focused strategies as a result of the rise of decentralized and digital clinical research. These models present a once-in-a-lifetime chance to revolutionize drug development by utilizing advancements like wearable sensors, telemedicine, electronic consent, remote monitoring, and mobile health apps. Decentralized clinical trials (DCTs) increase the speed and relevancy of clinical insights by facilitating the enrollment of patients from a wider range of demographics, lowering logistical costs, and enabling the real-time collecting of real-world data. This development has the potential to improve participant retention and compliance while drastically cutting trial durations and operating expenses. But there are challenges associated with this paradigm change. Navigating a changing global regulatory environment, protecting data privacy and integrity, closing the digital literacy gap, and building dependable technology infrastructure across diverse populations and geographical areas are some of the major issues. Furthermore, considerable preparation and supervision are needed to ensure that remotely performed trials respect ethical norms and scientific rigor. The dual nature of these developments is critically examined in this review, which emphasizes both the intricate obstacles and the transformational advantages. To get past these obstacles and realize the full potential of decentralized and digital approaches in pharmaceutical research, stakeholders must take a calculated, cooperative approach.

Keywords: Decentralized Clinical Trials, Digital Health Technologies, Pharmacological Research, Telemedicine, Real-World Data, Patient-Centric Trials



Figure 1: Difference between traditional clinical trials and decentralized clinical trials.

Introduction

Traditional clinical trials, with their reliance on centralized physical sites, often face significant hurdles in patient recruitment, retention, and geographical limitations. The advent of digital health technologies has paved the way for decentralized clinical trials (DCTs), where some or all trial-related activities occur outside traditional clinical sites, often at the participant's home or a local healthcare facility (U.S. FDA DCT, 2023). This shift holds immense promise for pharmacological research, enabling faster drug development, broader patient access, and the collection of richer, real-world data [1]. Clinical trials (CTs) are essential for determining the efficacy and safety of therapeutic interventions. However, several CT processes related to operations, data collection, participant recruitment, and prevention of loss to follow- up are suboptimal and hamper the clinical development of new interventions. Current pro cesses for participant identification, recruitment, and follow- up are expensive and often burdensome for participants, which may lead to low participation and retention. Furthermore, meeting recruitment targets is challenging, and this can lead to underpowered CTs, and CT discontinuation. Together, these factors have scientific, ethical, and financial implications that can hinder timely access to new therapeutic interventions [2]. In conventional clinical trials, participants visit investigational sites, often located in large medical facilities in metropolitan areas.. The centralization of operations in such locations far away from where potential participants live may hinder participation. DCT use in clinical trials promises to address a number of key drug development challenges. In addition to improving patient access and participation convenience, DCT solutions may also improve patient adherence to the protocol and may increase overall retention rates [3]. DCTs enable clinical research data to be collected more easily and faster, offering the opportunity to interrogate and draw insights from the data sooner, reduce the number of patients required, and increase statistical power.

Table 1. Opportunities and Challenges in Decentralized and Digital Clinical Research

Sr. no.	Opportunities	Challenges
1	Increased Patient Accessibility and Diversity	Evolving Regulatory and Compliance Landscape
2	Enhanced Data Collection and Real- World Insights	Data Quality, Integrity, and Security
3	Faster Trial Timelines and Cost Savings	Technological Infrastructure and Interoperability
4	Improved Patient Engagement and Satisfaction	Patient Engagement and Support

Opportunities in Decentralized and Digital Clinical Research

The integration of digital tools and decentralized methodologies brings forth several compelling opportunities for pharmacology:

1. Increased Patient Accessibility and Diversity

One of the most significant advantages of DCTs is their ability to reach a wider and more diverse patient population. Traditional trials often struggle with low recruitment and retention rates due to geographical and logistical barriers. DCTs overcome these by:

- Minimizing in-person visits: This reduces patient burden, travel time, and associated costs, making participation feasible for individuals in rural areas, those with mobility limitations, or those with demanding

schedules [4].

- Broadening demographic reach: By removing site-centric constraints, DCTs enable participation from a wider demographic, including underserved populations, leading to more generalizable study results [5].
- Enhanced recruitment and retention: Studies have shown that DCTs can significantly increase patient enrollment (e.g., a 2023 study cited by Ideagen found a 30% increase) and improve retention rates due to the reduced burden and increased convenience for participants [6].

2. Enhanced Data Collection and Real-World Insights

Digital technologies empower researchers to collect continuous, real-time data, offering a more comprehensive and accurate representation of participants' health status in their natural environment.

- Wearable sensors and mHealth apps: Devices like smartwatches and fitness trackers can continuously monitor vital signs, activity levels, sleep patterns, and other physiological parameters, providing longitudinal datasets far richer than intermittent site visits [7].
- Electronic Patient-Reported Outcomes (ePROs) and eCOAs: These digital tools allow for direct and timely capture of patient-reported data, improving accuracy and reducing recall bias [8].
- Digital biomarkers: Algorithmically generated indicators derived from passively collected data from connected devices can offer novel insights into disease progression and treatment response, as seen in applications by pharmaceutical companies like Pfizer and Novartis.
- Real-world evidence (RWE): The continuous monitoring and data collection in real- world settings strengthen the evidence base for regulatory submissions and provide a better understanding of drug efficacy and safety in diverse populations [9].

3. Faster Trial Timelines and Cost Savings

DCTs can significantly streamline the drug development process, leading to reduced timelines and lower costs.

- Accelerated recruitment: Improved accessibility and convenience lead to faster patient enrolment [10].
- Reduced operational costs: Eliminating or minimizing physical site expenses, administrative burdens, and travel reimbursements for participants contributes to significant cost savings.
- Efficient data management: Automation of data collection and remote monitoring reduces manual data entry and associated errors, leading to more efficient data processing and analysis [11].
- Improved decision-making: Continuous, real-time data allows for early detection of adverse events and better insights into drug response, enabling more informed decisions about trial progression or termination.
- Shortened Trial Timelines: Research indicates DCTs often reduce overall trial durations by up to 30%—meaning months saved in critical path phases. Tufts analysis found that saving just 1–3 months in Phase II or III can yield a 5–14× net financial return compared to technology investment.

4. Improved Patient Engagement and Satisfaction

DCTs can enhance the patient experience by offering greater flexibility and control, leading to higher engagement and adherence to study protocols.

- Convenience and comfort: Participants can engage with the study from their homes, reducing the disruption to their daily lives [12].
- Personalized support: Digital platforms can provide tailored educational materials, reminders, and direct communication channels with study staff, fostering a sense of empowerment and involvement.

- Empowered participation: Patients can take a more active role in their own health monitoring and data reporting, potentially leading to increased satisfaction.
- Enhanced Communication & Support: Digital trials often include chat lines, helplines, and real-time virtual check-ins. Quick access to study staff reassures participants that questions or concerns will be addressed swiftly, which cultivates engagement and confidence in the process [13].

Challenges in Decentralized and Digital Clinical Research

Despite the numerous opportunities, the adoption of decentralized and digital approaches in pharmacology is not without its challenges:

1. Evolving Regulatory and Compliance Landscape

The regulatory framework for clinical trials was primarily designed for traditional site-based studies, leading to ambiguities and inconsistencies when applied to DCTs [14].

- Lack of consistent global guidelines: The variability in regulatory requirements across different countries can create complexity and hurdles for multinational trials.
- Data authentication and privacy: Ensuring the authenticity, integrity, and privacy of remotely collected data, especially with diverse digital tools, is a significant concern [15].
- Investigator responsibilities: Defining the roles and responsibilities of investigators, sponsors, and other stakeholders in a decentralized model requires clear guidance.
- Technology validation: Digital health technologies used in DCTs require rigorous validation to ensure they meet regulatory standards for accuracy, reliability, and security [16].
- Lack of Standardized Global Regulations: Regulatory guidelines for decentralized trials differ significantly across countries. What may be acceptable in one region (e.g., the U.S. FDA's guidance on remote monitoring) might be restricted or lack clarity in others (such as certain European or Asian countries). This inconsistency complicates the design and execution of multi-national studies, leading to delays in approvals or the need to adapt protocols for different jurisdictions.

2. Data Quality, Integrity, and Security

Collecting data from various remote sources and integrating it into a cohesive and reliable dataset poses challenges:

- Data heterogeneity: Data from different wearable devices, apps, and ePRO systems may vary in format and quality, requiring robust data integration and standardization strategies [17].
- Technical and clinical validation: Digital tools and sensors need to be technically and clinically validated to ensure they generate reproducible and relevant data.
- Cybersecurity risks: The increased reliance on digital platforms and remote data transmission heightens the risk of cyberattacks and data breaches, necessitating stringent cybersecurity measures.
- Ensuring data accuracy: The potential for user error or intentional misrepresentation when self-reporting data or using personal devices needs to be mitigated.

.

3. Technological Infrastructure and Interoperability

The successful implementation of DCTs depends on robust and interoperable technological infrastructure:

- Digital literacy and access: Not all patients have equal access to or comfort with digital technologies, potentially leading to digital divides and impacting inclusivity.
- Interoperability of platforms: Integrating data from multiple disparate digital platforms (e.g., eCOA, ePRO, EHR, wearable data) can be burdensome and requires seamless interoperability [18].
- Device management and support: Ensuring participants have the necessary devices, understand how to use them, and receive adequate technical support is crucial for trial adherence.
- System integration: The integration of clinical trial systems with mainstream healthcare infrastructure is essential for a seamless participant experience and efficient data flow.
- Infrastructure Limitations

  a. Inadequate Digital Access: Participants in rural or underserved regions may not have consistent access to high-speed internet or compatible digital devices. This digital divide can limit recruitment and create data collection gaps, reducing trial inclusivity and generalizability.

  b.System Downtime and Reliability: Maintaining uptime for various digital systems is critical in DCTs. Interruptions due to software updates, connectivity failures, or server issues can delay study procedures and affect data continuity [19].

4. Patient Engagement and Support

While DCTs can enhance engagement, maintaining long-term adherence and addressing patient-specific needs requires thoughtful strategies:

- Patient burden of self-monitoring: While reducing travel burden, DCTs shift more responsibility to patients for self-monitoring and data reporting, which can be challenging, especially for older or less tech-savvy populations.
- Digital literacy and training: Providing clear, user-friendly instructions and ongoing training for participants on how to use digital tools is essential [20].
- Maintaining human connection: While technology facilitates remote interaction, ensuring a sense of connection and support with investigators and study staff is vital to patient retention.
- Adverse event management: Establishing clear protocols for managing adverse events remotely and ensuring timely intervention remains a critical consideration.

5. Operational and Cultural Shifts

Implementing DCTs requires a fundamental shift in operational models and a change in mindset within research organizations:

- Organizational design: A clear strategy for developing DCT infrastructure and ensuring proper integration of technology is necessary to avoid poorly integrated systems.
- Cross-functional collaboration: DCTs are inherently cross-functional, demanding enhanced collaboration across internal departments (e.g., clinical operations, IT, regulatory) and external partners (e.g., CROs, technology vendors) [21].

- Training for research staff: Research teams need adequate training on digital tools, remote monitoring techniques, and patient engagement strategies in a decentralized setting.

- Skepticism and resistance to change: Overcoming inherent skepticism and resistance to adopting new methodologies within the clinical research community can be a significant hurdle.

Conclusion

Decentralized and digital clinical research represents a transformative evolution in pharmacology, offering a powerful avenue to accelerate drug development, increase patient access and diversity, and generate richer, real-world data. The opportunities for enhanced efficiency, cost savings, and patient-centricity are compelling. However, the successful and ethical implementation of DCTs hinges on addressing key challenges related to regulatory harmonization, robust data governance, technological infrastructure, and effective patient engagement strategies. As the industry continues to innovate and regulatory bodies adapt, a collaborative and proactive approach will be essential to fully unlock the immense potential of decentralized and digital clinical research in shaping the future of pharmacology.

References

1. 83bar. (2022, November 15). *Benefits of virtual clinical trials vs. traditional clinical trials*. https://www.83bar.com/benefits-of-virtual-clinical-trials-vs-traditional-clinical- trials/
2. Biomapas. (n.d.). *What are the challenges of decentralized clinical trials?* Retrieved June 5, 2025, from https://www.biomapas.com/what-are-the-challenges-of- decentralized-clinical-trials/
3. Clinical Research News. (2023, November 3). *Decentralized clinical trials: Navigating the regulatory landscape for efficient and patient-centric research*. https://www.clinicalresearchnewsonline.com/news/2023/11/03/decentralized-clinical-trials-navigating-the-regulatory-landscape-for-efficient-and-patient-centric-research
4. Weber, Ditte & Nøhr, Christian. (2023). Decentralized Clinical Trials: Potentials for Equity in Digital Health. Studies in health technology and informatics. 304. 91-95. 10.3233/SHTI230378.
5. Stern AD, Trusheim M. Transformation of the Clinical Trial Enterprise: Lessons Learned from the COVID-19 Pandemic: Final Report [Internet]. Washington (DC):Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2024 Feb 9. 4, Decentralized clinical trials and digital health technologies. Available from: https://www.ncbi.nlm.nih.gov/books/NBK609002/?utm_source=chatgpt.com
6. Wikipedia contributors. (2025, April 23). Dynamic consent. In *Wikipedia, The Free Encyclopedia* Retrieved13:37, June 13, 2025, https://en.wikipedia.org/w/index.php?title=Dynamic_consent&oldid=128694253 4
7. Girardin Jean-Louis, Azizi A. Seixas, The value of decentralized clinical trials: Inclusion, accessibility, and innovation.*Science*385,eadq4994(2024).DOI:10.1126/science.adq4994
8. Miyata BL, Tafuto B, Jose N. Methods and perceptions of success for patient recruitment in decentralized clinical studies. J Clin Transl Sci. 2023 Oct 6;7(1):e232. doi: 10.1017/cts.2023.643. PMID: 38028356; PMCID: PMC10643920.

9. FDA. (2023). *Decentralized Clinical Trials for Drugs, Biological Products, and Devices: Guidance for Industry, Investigators, and Other Stakeholders.* Retrieved from: https://www.fda.gov/media/167575/download
10. Medidata. (2022). *Ensuring Data Integrity in Decentralized Clinical Trials.* https://www.medidata.com/en/insight/ensuring-data-integrity-in-decentralized- clinical-trials/
11. Coravos, A., et al. (2020). *Modernizing clinical trials with digital tools: Decentralized trials and real-world evidence.* NPJ Digital Medicine, 3(1), 1–7. https://doi.org/10.1038/s41746-020-0288-5
12. Freyrs Solutions. (2025, February 12). *Decentralized clinical trials: Regulatory challenges and solutions*. https://www.freyrsolutions.com/blog/decentralized-clinical- trials-regulatory-challenges-and-solutions
13. Frontiers. (2022, December 14). *Decentralized clinical trials (DCTs): A few ethical considerations*. https://www.frontiersin.org/journals/public- health/articles/10.3389/fpubh.2022.1081150/full
14. Ideagen. (2025, March 26). *Decentralized clinical trials: Challenges and opportunities in the future of clinical research*. https://www.ideagen.com/thought- leadership/blog/decentralized-clinical-trials-challenges
15. Lindus Health. (n.d.). *The advantages of conducting a digital clinical trial*. Retrieved June 5, 2025, from https://www.lindushealth.com/blog/the-advantages-of-conducting- a-digital-clinical-trial
16. Merck. (n.d.). *Digitally enabled, patient‑centric clinical trials: Shifting the drug development paradigm*. Retrieved June 5, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7993267/
17. Number Analytics. (2025, March 28). *Future of decentralized trials in pharma & health*. https://www.numberanalytics.com/blog/future-decentralized-trials-pharma- health
18. PubMed Central. (2023, September 22). *Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: a qualitative study*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10533674/

19.U.S. FDA DCT. (2023). *Decentralized clinical trials for drugs, biologics, and devices*. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs- biologics-and-devices

19. Merck. (n.d.). *Digitally enabled, patient‑centric clinical trials: Shifting the drug development paradigm*. Retrieved June 5, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7993267/
20. Number Analytics. (2025, March 28). *Future of decentralized trials in pharma & health*. https://www.numberanalytics.com/blog/future-decentralized-trials-pharma- health
21. PubMed Central. (2023, September 22). *Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: a qualitative study*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10533674/\
22. U.S. FDA DCT. (2023). *Decentralized clinical trials for drugs, biologics, and devices*. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs- biologics-and-devices
23. Merck. (n.d.). *Digitally enabled, patient‑centric clinical trials: Shifting the drug development paradigm*. Retrieved June 5, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7993267/
24. Number Analytics. (2025, March 28). *Future of decentralized trials in pharma & health*. https://www.numberanalytics.com/blog/future-decentralized-trials-pharma- health
25. PubMed Central. (2023, September 22). *Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: a qualitative study*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10533674/
26. U.S. FDA DCT. (2023). *Decentralized clinical trials for drugs, biologics, and devices*.U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs- biologics-and-devices
27. Sho Iwaki, Daisuke Kawakita, Toshitaka Nagao, Yuichiro Tada, Yoshitaka Honma, Mizuo Ando, Takuma Matoba, Kiyoshi Minohara, Satsuki Nakano, Takayuki Murase, Shinichi Iwasaki, Hiroshi Inagaki, Comprehensive genomic profiling of salivary gland carcinoma: Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan, International Journal of Cancer, 10.1002/ijc.34972, 155, 5, (871-882), (2024).

28. Copland RR, Hanke S, Rogers A, Mpaltadoros L, Lazarou I, Zeltsi A, Nikolopoulos S, MacDonald TM, Mackenzie IS The Digital Platform and Its Emerging Role in Decentralized Clinical Trials J Med Internet Res 2024;26:e47882 doi: 10.2196/47882
29. Underhill C, Freeman J, Dixon J, et al. Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access. JAMA Oncol. 2024;10(4):526–530. doi:10.1001/jamaoncol.2023.6565
30. Pritibha Singh, Oleksandr Sverdlov, Robert A. Beckman, Andrea M. Burden, Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey, Clinical and Translational Science, 10.1111/cts.70241, 18, 5, (2025).
31. McCarthy MW, Lindsell CJ, Rajasingham R, Stewart TG, Boulware DR, Naggie S. Progress toward realizing the promise of decentralized clinical trials. *Journal of Clinical and Translational Science*. 2024;8(1):e19. doi:10.1017/cts.2023.706
32. Ghadessi, M., Di, J., Wang, C. *et al.* Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA- IDSWG) perspective. *Orphanet J Rare Dis* 18, 79 (2023). https://doi.org/10.1186/s13023-023-02693-7
33. Sherry Fu et al. Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual- First Paradigm?. *JCO* 41, 181-185(2023). DOI:10.1200/JCO.22.00358
34. Cummins MR, Soni H, Ivanova J, et al. Narrative review of telemedicine applications in decentralized research. *Journal of Clinical and Translational Science*. 2024;8(1):e30. doi:10.1017/cts.2024.3
35. Daly B, Brawley OW, Gospodarowicz MK, et al. Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Netw Open. 2024;7(4):e246228. doi:10.1001/jamanetworkopen.2024.6228
36. Sundquist, S., Batist, G., Brodeur-Robb, K., Dyck, K., Eigl, B. J., Lee, D. K., Limoges, J., Longstaff, H., Pankovich, J., Sadura, A., Sullivan, P., & Dancey, J. E. (2021). CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada.*Current Oncology*, *28*(5),3857-386https://doi.org/10.3390/curroncol28050329
37. Kehoe, L., Calvert, S.B., Hallinan, Z. *et al.* Adoption of Decentralization: Are Our Perceptions Holding Us Back?. *Ther Innov Regul Sci* (2024). https://doi.org/10.1007/s43441-024-00636-3
38. Ghadessi, M., Di, J., Wang, C. *et al.* Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA- IDSWG) perspective. *Orphanet J Rare Dis* 18, 79 (2023). https://doi.org/10.1186/s13023-023-02693-7
39. Sherry Fu et al. Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual- First Paradigm?. *JCO* 41, 181-185(2023). DOI:10.1200/JCO.22.00358
40. Cummins MR, Soni H, Ivanova J, et al. Narrative review of telemedicine applications in decentralized research. *Journal of Clinical and Translational Science*. 2024;8(1):e30. doi:10.1017/cts.2024.3
41. Daly B, Brawley OW, Gospodarowicz MK, et al. Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Netw Open. 2024;7(4):e246228. doi:10.1001/jamanetworkopen.2024.6228
42. Sundquist, S., Batist, G., Brodeur-Robb, K., Dyck, K., Eigl, B. J., Lee, D. K., Limoges, J., Longstaff, H., Pankovich, J., Sadura, A., Sullivan, P., & Dancey, J. E. (2021). CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada.*Current Oncology*, *28*(5), 3857-3865 https://doi.org/10.3390/curroncol28050329
43. Kehoe, L., Calvert, S.B., Hallinan, Z. *et al.* Adoption of Decentralization: Are Our Perceptions Holding Us Back?. *Ther Innov Regul Sci* (2024). https://doi.org/10.1007/s43441-024-00636-3